Depo-Provera

DepoProvera carries an FDA black box warning—the strongest safety warning—advising it should not be used for more than two years unless no other birth control method is suitable. The warning is due to the risk of bone mineral density loss, which may not be fully reversible.

Despite this, some women are prescribed DepoProvera for longer periods. While the U.S. label does not mention it, Canadian and European health authorities warn of a possible link between DepoProvera and meningioma—a typically benign tumor that forms in the membranes covering the brain and spinal cord.

Recent studies suggest that intramuscular DepoProvera injections may significantly increase the risk of developing meningiomas, especially with longterm use.

Meningiomas are tumors that develop in the meninges—the protective membranes surrounding the brain and spinal cord. They are often slowgrowing, and symptoms may not appear until the tumor becomes large enough to press on nearby structures. Depending on size and location, meningiomas can cause headaches, vision problems, seizures, weakness, or even strokes.

Diagnosis is typically made through imaging tests such as MRI or CT scans. While most meningiomas are benign, they can still lead to serious and sometimes permanent neurological complications if left untreated.

Cerebral Meningiomas

These tumors form in the layers surrounding the brain. As they enlarge, they can put pressure on brain tissue, leading to severe and debilitating symptoms. Treatment often requires a craniotomy—a major surgical procedure to remove the tumor—which carries its own risks and potential postoperative complications.

Spinal Meningiomas

Spinal meningiomas develop in the meninges along the spinal cord. Like cerebral meningiomas, they are usually benign but can compress the spinal cord or nerves, causing pain, weakness, or sensory changes. Treatment often involves surgical removal, and in some cases, radiation therapy may be recommended to prevent recurrence.